دورية أكاديمية
The Spectrum of Neurological and White Matter Changes and Premutation Status Categories of Older Male Carriers of the FMR1 Alleles Are Linked to Genetic (CGG and FMR1 mRNA) and Cellular Stress (AMPK) Markers.
| العنوان: | The Spectrum of Neurological and White Matter Changes and Premutation Status Categories of Older Male Carriers of the FMR1 Alleles Are Linked to Genetic (CGG and FMR1 mRNA) and Cellular Stress (AMPK) Markers. |
|---|---|
| المؤلفون: | Loesch DZ; Department of Psychology and Counselling, School of Psychology and Public Health, College of Science Health and Engineering, La Trobe University, Melbourne, VIC, Australia., Trost N; Medical Imaging Department, St Vincent's Hospital, Melbourne, VIC, Australia., Bui MQ; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia., Hammersley E; Department of Psychology and Counselling, School of Psychology and Public Health, College of Science Health and Engineering, La Trobe University, Melbourne, VIC, Australia., Lay ST; Discipline of Microbiology, Department of Physiology Anatomy and Microbiology, School of Life Sciences, College of Science Health and Engineering, La Trobe University, Melbourne, VIC, Australia., Annesley SJ; Discipline of Microbiology, Department of Physiology Anatomy and Microbiology, School of Life Sciences, College of Science Health and Engineering, La Trobe University, Melbourne, VIC, Australia., Sanislav O; Discipline of Microbiology, Department of Physiology Anatomy and Microbiology, School of Life Sciences, College of Science Health and Engineering, La Trobe University, Melbourne, VIC, Australia., Allan CY; Discipline of Microbiology, Department of Physiology Anatomy and Microbiology, School of Life Sciences, College of Science Health and Engineering, La Trobe University, Melbourne, VIC, Australia., Tassone F; UC Davis MIND Institute, Sacramento, CA, United States., Chen ZP; St Vincent's Institute of Medical Research, Melbourne, VIC, Australia., Ngoei KRW; St Vincent's Institute of Medical Research, Melbourne, VIC, Australia., Kemp BE; St Vincent's Institute of Medical Research, Melbourne, VIC, Australia., Francis D; Cytomolecular Diagnostic Research, Victorian Clinical Genetics Services, Melbourne, VIC, Australia., Fisher PR; Discipline of Microbiology, Department of Physiology Anatomy and Microbiology, School of Life Sciences, College of Science Health and Engineering, La Trobe University, Melbourne, VIC, Australia., Storey E; Department of Medicine (Neuroscience), Monash University, Melbourne, VIC, Australia. |
| المصدر: | Frontiers in genetics [Front Genet] 2018 Nov 12; Vol. 9, pp. 531. Date of Electronic Publication: 2018 Nov 12 (Print Publication: 2018). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101560621 Publication Model: eCollection Cited Medium: Print ISSN: 1664-8021 (Print) Linking ISSN: 16648021 NLM ISO Abbreviation: Front Genet Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Research Foundation. |
| مستخلص: | The fragile X premutation (PM) allele contains a CGG expansion of 55-200 repeats in the FMR1 gene's promoter. Male PM carriers have an elevated risk of developing neurological and psychiatric changes, including an approximately 50% risk of the fragile X-associated tremor/ataxia syndrome (FXTAS). The aim of this study was to assess the relationships of regional white matter hyperintensities ( wmhs ) semi-quantitative scores, clinical status, motor (UPDRS, ICARS, Tremor) scales, and cognitive impairments, with FMR1 -specific genetic changes, in a sample of 32 unselected male PM carriers aged 39-81 years. Half of these individuals were affected with FXTAS, while the non-FXTAS group comprised subcategories of non-affected individuals and individuals affected with non-syndromic changes. The dynamics of pathological processes at the cellular level relevant to the clinical status of PM carriers was investigated using the enzyme AMP-activated protein kinase (AMPK), which is a highly sensitive cellular stress-sensing alarm protein. This enzyme, as well as genetic markers - CGG repeat number and the levels of the FMR1 mRNA - were assessed in blood lymphoblasts. The results showed that the repeat distribution for FXTAS individuals peaked at 85-90 CGGs; non-FXTAS carriers were distributed within the lowest end of the PM repeat range, and non-syndromic carriers assumed an intermediate position. The size of the CGG expansion was significantly correlated, across all three categories, with infratentorial and total wmhs and with all motor scores, and the FMR1 mRNA levels with all the wmh scores, whilst AMPK activity showed considerable elevation in the non-FXTAS combined group, decreasing in the FXTAS group, proportionally to increasing severity of the wmhs and tremor/ataxia. We conclude that the size of the CGG expansion relates to the risk for FXTAS, to severity of infratentorial wmhs lesions, and to all three motor scale scores. FMR1 mRNA shows a strong association with the extent of wmhs , which is the most sensitive marker of the pathological process. However, the AMPK activity findings - suggestive of a role of this enzyme in the risk of FXTAS - need to be verified and expanded in future studies using larger samples and longitudinal assessment. |
| References: | Mol Biol Cell. 2007 May;18(5):1874-86. (PMID: 17332500) Eur J Med Genet. 2018 Nov;61(11):674-679. (PMID: 29223504) Neurodegener Dis. 2017;17(1):22-30. (PMID: 27602566) Am J Med Genet B Neuropsychiatr Genet. 2011 Jun;156B(4):502-6. (PMID: 21445959) Neurology. 2012 Oct 30;79(18):1898-907. (PMID: 23077007) Ann Neurol. 2005 Aug;58(2):326-30. (PMID: 16049924) J Neurol. 2008 Sep;255(9):1302-8. (PMID: 18825439) Clin Genet. 2005 May;67(5):412-7. (PMID: 15811008) J Med Genet. 2007 Mar;44(3):200-4. (PMID: 16905681) Am J Hum Genet. 2000 Jan;66(1):6-15. (PMID: 10631132) Cell Death Dis. 2014 Jan 16;5:e997. (PMID: 24434520) Mov Disord. 2004 Feb;19(2):190-2. (PMID: 14978674) Mov Disord. 1994 Jan;9(1):89-91. (PMID: 8139610) Exp Neurol. 2017 Dec;298(Pt A):31-41. (PMID: 28844606) Arch Neurol. 2012 Apr;69(4):482-9. (PMID: 22491193) Stroke. 2001 Jun;32(6):1318-22. (PMID: 11387493) Biochem J. 2010 Aug 1;429(3):545-52. (PMID: 20513237) Cerebellum. 2016 Oct;15(5):623-31. (PMID: 27372099) J Med Genet. 2004 Apr;41(4):e43. (PMID: 15060119) Nat Rev Neurol. 2016 Jul;12(7):403-12. (PMID: 27340021) Brain. 2011 Mar;134(Pt 3):863-78. (PMID: 21354978) Clin Genet. 2009 Nov;76(5):471-6. (PMID: 19796183) Neurodegener Dis. 2014;14(2):67-76. (PMID: 24401315) Curr Opin Cell Biol. 2015 Apr;33:1-7. (PMID: 25259783) J Biol Chem. 1996 Jan 12;271(2):611-4. (PMID: 8557660) Nat Clin Pract Neurol. 2007 Feb;3(2):107-12. (PMID: 17279084) JAMA. 2004 Jan 28;291(4):460-9. (PMID: 14747503) J Clin Neurosci. 2016 Jan;23:162-164. (PMID: 26439425) Oncotarget. 2017 Oct 23;8(68):112477-112486. (PMID: 29348841) J Neurol Sci. 2015 May 15;352(1-2):19-28. (PMID: 25847019) Neurology. 2008 Apr 15;70(16 Pt 2):1397-402. (PMID: 18057320) Hum Mol Genet. 2011 Jun 1;20(11):2161-70. (PMID: 21389081) JAMA Neurol. 2013 Aug;70(8):1022-9. (PMID: 23753897) Hum Mol Genet. 2011 Aug 1;20(15):3079-92. (PMID: 21558427) Mov Disord. 2013 Aug;28(9):1278-84. (PMID: 23649693) Curr Opin Neurol. 2014 Oct;27(5):515-23. (PMID: 25188012) Neurobiol Aging. 2017 Jul;55:11-19. (PMID: 28391068) Nat Rev Mol Cell Biol. 2012 Mar 22;13(4):251-62. (PMID: 22436748) J Neurodev Disord. 2014;6(1):28. (PMID: 25136377) AJNR Am J Neuroradiol. 2002 Nov-Dec;23(10):1757-66. (PMID: 12427636) EMBO J. 2009 Mar 18;28(6):677-85. (PMID: 19197243) Mol Cytogenet. 2008 Apr 08;1:5. (PMID: 18471319) Neurobiol Aging. 2013 Jun;34(6):1700-7. (PMID: 23298734) Brain. 2006 Jan;129(Pt 1):243-55. (PMID: 16332642) Am J Med Genet A. 2009 Oct;149A(10):2306-10. (PMID: 19760650) J Neurol Sci. 1993 Jan;114(1):7-12. (PMID: 8433101) Lancet Neurol. 2013 Aug;12(8):786-98. (PMID: 23867198) Am J Med Genet. 1999 May 28;84(3):240-4. (PMID: 10331600) Neurology. 2006 Oct 24;67(8):1426-31. (PMID: 17060569) Biochim Biophys Acta. 2014 Apr;1840(4):1331-44. (PMID: 24513455) Neuron. 2013 May 8;78(3):440-55. (PMID: 23602499) Acta Neuropathol Commun. 2016 Feb 25;4:18. (PMID: 26916632) Hum Mol Genet. 2007 Dec 15;16(24):3174-87. (PMID: 17921506) J Neurol Sci. 1997 Feb 12;145(2):205-11. (PMID: 9094050) Mov Disord. 2007 Apr 30;22(6):833-8. (PMID: 17343274) Clin Genet. 2013 Oct;84(4):382-5. (PMID: 23198693) Neuroimage. 2013 Jan 15;65:288-98. (PMID: 23063447) Dis Model Mech. 2016 Nov 1;9(11):1295-1305. (PMID: 27638668) J Clin Epidemiol. 2014 Aug;67(8):850-7. (PMID: 24831050) Biochim Biophys Acta. 2015 Mar;1852(3):529-40. (PMID: 25536029) Acta Neuropathol. 2014 Oct;128(4):525-41. (PMID: 24806409) |
| معلومات مُعتمدة: | R01 HD036071 United States HD NICHD NIH HHS |
| فهرسة مساهمة: | Keywords: AMPK kinase; CGG repeats; FMR1 mRNA; FMR1 premutation; cellular stress; cognitive status; motor scores; white matter hyperintensities |
| تواريخ الأحداث: | Date Created: 20181129 Latest Revision: 20240403 |
| رمز التحديث: | 20240403 |
| مُعرف محوري في PubMed: | PMC6241173 |
| DOI: | 10.3389/fgene.2018.00531 |
| PMID: | 30483310 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-8021 |
|---|---|
| DOI: | 10.3389/fgene.2018.00531 |